Comparative Pharmacology
Head-to-head clinical analysis: JYLAMVO versus NIPENT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JYLAMVO versus NIPENT.
JYLAMVO vs NIPENT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Purine nucleoside analog that inhibits DNA synthesis and repair by incorporating into DNA and inhibiting ribonucleotide reductase and DNA polymerases.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
5 mg/m2 intravenously over 20-30 minutes every 3 weeks.
None Documented
None Documented
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 5-8 hours in patients with normal renal function. Clinically, the half-life may be prolonged in renal impairment, requiring dose adjustments.
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Primarily renal excretion; approximately 50-70% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination accounts for <5%.
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent